JP2022008641A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022008641A5 JP2022008641A5 JP2021159462A JP2021159462A JP2022008641A5 JP 2022008641 A5 JP2022008641 A5 JP 2022008641A5 JP 2021159462 A JP2021159462 A JP 2021159462A JP 2021159462 A JP2021159462 A JP 2021159462A JP 2022008641 A5 JP2022008641 A5 JP 2022008641A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- level
- sample
- fold
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461972091P | 2014-03-28 | 2014-03-28 | |
| US61/972,091 | 2014-03-28 | ||
| JP2017502940A JP6953305B2 (ja) | 2014-03-28 | 2015-03-27 | Ｌ−２−ヒドロキシグルタル酸及びストレス誘発性代謝 |
| PCT/US2015/023038 WO2015148950A1 (en) | 2014-03-28 | 2015-03-27 | L-2-hydroxyglutarate and stress induced metabolism |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017502940A Division JP6953305B2 (ja) | 2014-03-28 | 2015-03-27 | Ｌ−２−ヒドロキシグルタル酸及びストレス誘発性代謝 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022008641A JP2022008641A (ja) | 2022-01-13 |
| JP2022008641A5 true JP2022008641A5 (https=) | 2022-02-14 |
| JP7208323B2 JP7208323B2 (ja) | 2023-01-18 |
Family
ID=54196451
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017502940A Expired - Fee Related JP6953305B2 (ja) | 2014-03-28 | 2015-03-27 | Ｌ−２−ヒドロキシグルタル酸及びストレス誘発性代謝 |
| JP2021159462A Active JP7208323B2 (ja) | 2014-03-28 | 2021-09-29 | Ｌ－２－ヒドロキシグルタル酸及びストレス誘発性代謝 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017502940A Expired - Fee Related JP6953305B2 (ja) | 2014-03-28 | 2015-03-27 | Ｌ−２−ヒドロキシグルタル酸及びストレス誘発性代謝 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10450596B2 (https=) |
| EP (1) | EP3122893B1 (https=) |
| JP (2) | JP6953305B2 (https=) |
| AU (1) | AU2015237241B2 (https=) |
| CA (1) | CA2943823C (https=) |
| WO (1) | WO2015148950A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012340192B2 (en) | 2011-11-18 | 2016-04-07 | Memorial Sloan-Kettering Cancer Center | 2-hydroxyglutarate as a biomarker for chronic hypoxia |
| AU2015237241B2 (en) | 2014-03-28 | 2021-07-29 | Memorial Sloan-Kettering Cancer Center | L-2-hydroxyglutarate and stress induced metabolism |
| US20200375963A1 (en) * | 2017-02-10 | 2020-12-03 | Health Research, Inc. | Targeting mitochondrial complex ii to reduce effects of chronic hypoxia |
| US10500318B1 (en) * | 2018-07-03 | 2019-12-10 | Temple Therapeutics BV | Dosing regimens for treating hypoxia-associated tissue damage |
| JP6977999B2 (ja) * | 2018-08-22 | 2021-12-08 | 国立大学法人京都大学 | 胚培養培地、及び胚培養方法 |
| FR3097739B1 (fr) * | 2019-06-25 | 2022-03-04 | Lnc Therapeutics | Bactéries du microbiote intestinal et composition en contenant pour son utilisation dans la prévention et/ou le traitement de maladies caractérisées par l’excès de 2-hydroxyglutarate |
| CN112830958B (zh) * | 2021-02-05 | 2022-06-14 | 山东大学 | 一种特异性响应于d-2-羟基戊二酸的转录调控因子及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6855510B2 (en) | 2001-03-20 | 2005-02-15 | Dana Farber Cancer Institute, Inc. | Pharmaceuticals and methods for treating hypoxia and screening methods therefor |
| US20060084123A1 (en) | 2001-12-13 | 2006-04-20 | Harris Adrian L | MN and hypoxia |
| WO2004046729A2 (en) | 2002-11-21 | 2004-06-03 | The University Of Leicester | Bodily fluid markers of tissue hypoxia |
| US20090186358A1 (en) | 2007-12-21 | 2009-07-23 | Wyeth | Pathway Analysis of Cell Culture Phenotypes and Uses Thereof |
| US20120121515A1 (en) | 2009-03-13 | 2012-05-17 | Lenny Dang | Methods and compositions for cell-proliferation-related disorders |
| SE534542C2 (sv) * | 2009-09-30 | 2011-09-27 | Calmark Sweden Ab | Testsystem för bestämning av hypoxiutlöst cellskada |
| EP2525790B1 (en) | 2009-10-21 | 2020-05-27 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
| WO2011143160A2 (en) | 2010-05-10 | 2011-11-17 | The Johns Hopkins University | Metabolic inhibitor against tumors having an idh mutation |
| US20120202883A1 (en) | 2011-01-20 | 2012-08-09 | Duke University | Effects of idh1 and idh2 mutations on the cellular metabolome |
| AU2012340192B2 (en) | 2011-11-18 | 2016-04-07 | Memorial Sloan-Kettering Cancer Center | 2-hydroxyglutarate as a biomarker for chronic hypoxia |
| JP2015505965A (ja) * | 2011-12-09 | 2015-02-26 | メタボロン，インコーポレイテッド | 腎癌のバイオマーカーおよびそれを用いる方法 |
| US8977473B2 (en) | 2012-08-29 | 2015-03-10 | Caterpillar Inc. | Pressure control strategy for dual fuel compression ignition engine and machine using same |
| AU2015237241B2 (en) | 2014-03-28 | 2021-07-29 | Memorial Sloan-Kettering Cancer Center | L-2-hydroxyglutarate and stress induced metabolism |
-
2015
- 2015-03-27 AU AU2015237241A patent/AU2015237241B2/en not_active Ceased
- 2015-03-27 CA CA2943823A patent/CA2943823C/en active Active
- 2015-03-27 US US15/129,167 patent/US10450596B2/en active Active
- 2015-03-27 JP JP2017502940A patent/JP6953305B2/ja not_active Expired - Fee Related
- 2015-03-27 WO PCT/US2015/023038 patent/WO2015148950A1/en not_active Ceased
- 2015-03-27 EP EP15768552.0A patent/EP3122893B1/en active Active
-
2019
- 2019-06-25 US US16/452,297 patent/US11788112B2/en active Active
-
2021
- 2021-09-29 JP JP2021159462A patent/JP7208323B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022008641A5 (https=) | ||
| Schaupp et al. | Longitudinal effects of elexacaftor/tezacaftor/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis | |
| Terracciano et al. | Asthma and COPD proteomics: current approaches and future directions | |
| JP6755240B2 (ja) | 新規分子バイオマーカーを使用して慢性閉塞性肺疾患（ｃｏｐｄ）を診断する方法 | |
| JP2017520774A5 (https=) | ||
| JP6755242B2 (ja) | 新規分子バイオマーカーを使用して慢性閉塞性肺疾患（ｃｏｐｄ）を診断する方法 | |
| Palmiere et al. | Endocan measurement for the postmortem diagnosis of sepsis | |
| Wu et al. | Analysis of thrombotic factors in severe acute respiratory syndrome (SARS) patients | |
| US12449425B2 (en) | Methods of treating or preventing serious symptoms from COVID-19 infection | |
| JP5221333B2 (ja) | 意識障害患者における病態の検出方法及び検出用キット | |
| Molanaei et al. | Metabolism of alprazolam (a marker of CYP3A4) in hemodialysis patients with persistent inflammation | |
| Kotlinska-Hasiec et al. | Disturbance in venous outflow from the cerebral circulation intensifies the release of blood-brain barrier injury biomarkers in patients undergoing cardiac surgery | |
| Gamil et al. | Increased serum levels of asymmetric dimethylarginine and symmetric dimethylarginine and decreased levels of arginine in Sudanese patients with essential hypertension | |
| Nakamura et al. | Circulating levels of advanced glycation end products (AGE) and interleukin-6 (IL-6) are independent determinants of serum asymmetric dimethylarginine (ADMA) levels in patients with septic shock | |
| CN112424609A (zh) | 卒中的血液生物标志物 | |
| Lozhkina et al. | Ceramides As Potential New Predictors of the Severity of Acute Coronary Syndrome in Conjunction with SARS-CoV-2 Infection | |
| Jain | Biomarkers of pulmonary diseases | |
| Morishima et al. | A direct oral anticoagulant edoxaban accelerated fibrinolysis via enhancement of plasmin generation in human plasma: dependent on thrombin-activatable fibrinolysis inhibitor | |
| Cai et al. | Resistive spontaneous breathing exacerbated lipopolysaccharide-induced lung injury in mice | |
| JP2017533431A (ja) | 細気管支炎後の喘息の診断のためのマーカーおよびその用途 | |
| US11634717B2 (en) | DNA aptamer specifically binding to TB7.7, and use thereof | |
| BR112021002281A2 (pt) | pro-adm para prognosticar o risco de uma condição médica requerendo hospitalização em pacientes com sintomas de doença infecciosa | |
| JP2023041741A (ja) | 重篤患者用の療法モニタリングマーカーとしてのｐｒｏ－ａｄｍ | |
| Lee et al. | Upregulation of Potassium Voltage‐Gated Channel Subfamily J Member 2 Levels in the Lungs of Patients With Idiopathic Pulmonary Fibrosis | |
| Bauer et al. | Systemic inflammatory response after bronchoalveolar lavage in critically ill patients |